WillItSurvive
Financial data and information services · United States

Clarivate

clarivate.com ↗

Clarivate sells patent, citation, and library data (Web of Science, Derwent) that institutions pay to access.

Losing its protection
Assessed 21 July 2026 · Evidence as of 21 July 2026
The structural protection is eroding.
On the recordSince 21 July 2026 · Checkable from Q4 2026 · Every call on the record Checkpoint: Altaris Life Sciences & Healthcare divestiture expected to close, reshaping revenue mix and debt load
The call

Clarivate's data and index franchises still get renewed, but heavy debt and flat growth mean the divestiture and refinancing matter more than any AI headline right now.

Clarivate owns databases that scientists, lawyers, and companies rely on for research information and patent data, and these customers are locked in by long contracts and habits that are hard to shake. The real competitor is not just Elsevier (which sells similar research tools) but also free websites like OpenAlex and smart AI tools like Claude that can do some of the same work for nothing. The key question is whether Clarivate's new AI products will bring in real new money or just keep existing customers from leaving, because the company is saddled with nearly three billion dollars in debt and hardly growing, which means it needs revenue wins to survive.

Why
01
AI pressure: OpenAlex, The Lens, Cypris.ai and generic models like Claude. Free and AI-native tools replicate citation and patent search at the edges, squeezing prices even as Clarivate bolts AI onto its own products. Could AI do the core job? Only partly.
02
Bigger players: Elsevier/RELX. Elsevier's Scopus and ScienceDirect compete head to head for the same library and researcher budgets, holding a steadier financial position. Could a giant copy it? No, they are blocked.
03
What protects it. Journal Impact Factor and Derwent patent index are embedded in institutional workflows and hard to switch away from quickly.
What would change this call
Altaris Life Sciences & Healthcare divestiture closes or slips past Q4 2026. Shows whether debt paydown and portfolio focus proceed on schedule or execution risk grows.
Q3 and Q4 2026 organic ACV growth figures reported. Reveals whether growth accelerates past 2% or stays flat/negative post-divestiture.
Any major library or institution publicly drops Web of Science or Journal Impact Factor subscription. Would indicate the core JIF/citation moat is cracking under open-access pressure.
Key numbers
  • Debt near $4.3-4.5B versus ~$1.49B market cap (2026-07-20)
  • Stock down 44% over trailing year (2026-07-20)
  • Organic ACV growth only ~2% in FY2025 (2026-02-24)
Named risks
  • Heavy debt load of $4.3 to 4.5 billion against $1.49 billion market cap creates leverage overhang. Severity: high
  • Flat organic growth (~2% ACV) leaves little cushion if pricing on JIF or core subscriptions cracks. Severity: high
  • Altaris divestiture could slip or fail regulatory approval before year-end 2026 target. Severity: medium
  • Open-access and AI-native niche entrants erode edges of core bibliometrics and life-sciences workflows. Severity: medium
  • Leadership transition in IP segment (Webster replacing Mourad) could disrupt execution through September 2026. Severity: low
Rivals, as read in July 2026
RivalDirectionEvidence
Elsevier/RELX (Scopus, ScienceDirect)contestingStable duopoly rival in bibliometrics; comparison article June 23, 2026 notes larger multidisciplinary index
Digital Science (Dimensions)contestingPositioned as third major player in research-workflow tools alongside Clarivate and Elsevier
OpenAlex, Crossref, The Lens (open access)losing toFree alternatives cited as pressuring citation-index pricing as of 2024 background analysis
Cypris.ailosing toAI-native competitor marketed explicitly as Derwent/Web of Science alternative, March 16, 2026
Salesmotionlosing toAI-native sales-intelligence tool marketed as cheaper Cortellis/DRG substitute, March 2, 2026
Questions people ask
Is Clarivate profitable in 2026?
Clarivate generated $628.5M operating cash flow and $365.3M free cash flow in FY2025 (reported Feb 24, 2026), but organic ACV growth was only about 2% and the stock fell roughly 28% year to date through July 20, 2026, reflecting weak underlying growth despite positive cash flow.
Is Clarivate a safe company to join right now?
Clarivate carries about $4.3 to $4.5 billion in long-term debt against a market cap near $1.49 billion as of July 20, 2026, and cut roughly 200 jobs in January 2025. It is mid-turnaround with a pending $600 million Life Sciences divestiture to Altaris, so stability depends on that deal closing and debt paydown succeeding.
Could AI replace Clarivate's products?
Third-party analysis from March 2026 claims 80 to 90 percent of daily BD research tasks in life sciences can already be served by AI on public data, but Clarivate's exclusive Journal Impact Factor and curated patent/regulatory datasets remain hard to replicate, per company statements as of April 2026.
Who owns Clarivate?
Clarivate Plc trades publicly on NYSE as CLVT with no parent company. Institutional investors hold about 85.72% of shares as of July 20, 2026, and Leonard Green & Partners LP holds roughly 16 to 18% based on late-2024 disclosures.
What is Clarivate's biggest competitor?
Elsevier (RELX), via Scopus and ScienceDirect, is Clarivate's closest direct rival in citation databases and research workflow tools, per a June 2026 comparison. Digital Science and open-access tools like OpenAlex and The Lens add further pricing pressure on Clarivate's core bibliometrics business.
Why is Clarivate selling its Life Sciences segment?
Clarivate announced a definitive agreement on July 6, 2026 to sell its Life Sciences & Healthcare segment to Altaris LLC for $600 million, expected to close by year-end 2026, explicitly to sharpen focus on AI-driven intelligence in Academia & Government and IP while using proceeds to reduce debt.
Timeline
  • 2026-07-15Clarivate wins multi-year modernization contract with France's Abes academic library agency
  • 2026-07-06Announces $600M sale of Life Sciences & Healthcare segment to Altaris LLC
  • 2026-06-20Simon Webster named President of IP segment, replacing Maroun Mourad
  • 2026-05-06Launches Web of Science Research Intelligence AI-native platform with 50+ partners
  • 2026-02-24Reports FY2025 results: $628.5M operating cash flow, ~2% organic ACV growth
  • 2025-12-04Presents full launch of Cortellis Regulatory AI Assistant
  • 2025-08-14Integrates Claude AI into Cortellis suite for regulatory intelligence
  • 2025-04-09Expands Academic AI Platform with agentic AI Agents for research
  • 2025-01-14Restructuring cuts about 200 jobs
  • 2019NYSE listing via SPAC merger with Churchill Capital Corp under ticker CLVT
Revision history
21 July 2026
First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.
In the same band
LiveRampRepRiskForsta
More in Financial data and information services →
Sources